(E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid | 1421691-11-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid
• CAS: 1421691-11-3
• 化学式: C₂₀H₃₀F₂O₄
• 分子量: 372.453
• InChiKey: WIUGSPUQKXSPDJ-JDFMTEHDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-[(1R,2R,5S)-2-(4,4-difluoro-3-hydroxyoctyl)-5-hydroxycyclopentyl]pentanal 在 sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 氢氟酸 、 碳酸氢钠 、 potassium bromide 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 水 、 甲苯 、 乙腈 为溶剂， 反应 19.75h， 生成 (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid
  参考文献：
  名称：

  [EN] METHOD FOR TREATING SCHIZOPHRENIA
  [FR] PROCÉDÉ DE TRAITEMENT DE LA SCHIZOPHRÉNIE

  摘要：

  本发明提供了一种新型脂肪酸衍生物。本发明还提供了在哺乳动物主体中治疗精神分裂症的有效量脂肪酸衍生物的用途。

  公开号：

  WO2013022079A1

文献信息

• Multilayer beads for pharmaceutical use
  申请人：Sucampo AG

  公开号：US11534404B2

  公开（公告）日：2022-12-27

  Multilayer beads for pharmaceutical use having a drug-in-polymer layer are disclosed. The disclosed multilayer beads for pharmaceutical use have (a) a core particle; (b) an optional barrier layer coated on the surface of the core particle; (c) a drug-in-polymer layer coated on the surface of the core or the barrier layer, (d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and (e) optionally one or more outer layers external to the drug-in-polymer layer or the sealant layer. The drug-in-polymer layer consists essentially of (i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or a mixture thereof. The drug-in-polymer layer may be solid dispersion of the drug in the polymer. Pharmaceutical compositions comprising a plurality of multilayer beads and a pharmaceutically acceptable excipient and methods of treating a gastrointestinal disorder are also disclosed.

  本发明公开了具有聚合体药物层的药用多层微珠。所公开的药用多层微珠具有：(a) 核心颗粒；(b) 涂在核心颗粒表面的任选阻隔层；(c) 涂在核心或阻隔层表面的聚合体药物层；(d) 涂在聚合体药物层表面的任选密封剂层；(e) 聚合体药物层或密封剂层外部的一个或多个外层。药包聚合物层主要包括：(i) 选自 15-酮前列腺素药物、13,14-二氢前列腺素药物和 13,14-二氢-15-酮前列腺素药物组的药物；(ii) 选自聚乙烯基吡咯烷酮、乙烯基吡咯烷酮-乙酸乙烯酯共聚物或其混合物组的聚合物。药物聚合物层可以是药物在聚合物中的固体分散体。还公开了包含多个多层微珠和药学上可接受的赋形剂的药物组合物以及治疗胃肠道疾病的方法。
• METHOD FOR TREATING SCHIZOPHRENIA
  申请人：UENO Ryuji

  公开号：US20130035393A1

  公开（公告）日：2013-02-07

  The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.
• METHOD FOR SUPPRESSING TUMORIGENICITY OF STEM CELLS
  申请人：SUCAMPO AG

  公开号：US20140371304A1

  公开（公告）日：2014-12-18

  A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing tumorigenicity of stem cells of a mammalian subject, which comprises contacting said stem cell with an effective amount of a fatty acid derivative, are provided.
• METHOD FOR TREATING NEUROPATHIC PAIN
  申请人：SUCAMPO AG

  公开号：US20150057351A1

  公开（公告）日：2015-02-26

  A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided.
• SELECTIVE TUMOR TREATMENT
  申请人：SUCAMPO AG

  公开号：US20150099802A1

  公开（公告）日：2015-04-09

  A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH), which comprises contacting said tumor cell with an effective amount of a fatty acid derivative, and a method for identifying a subject who would be responsive to a fatty acid derivative, comprising, (i) obtaining a biological sample from said subject; and (ii) measuring 15-hydroxyprostaglandin dehydrogenase (15-PGDH) level are provided.